RBC Capital Keeps Their Buy Rating on Tenet Healthcare (THC)

RBC Capital analyst Ben Hendrix maintained a Buy rating on Tenet Healthcare on February 17 and set a price target of $277.00. The company’s shares closed yesterday at $234.25.

President's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Hendrix is a 4-star analyst with an average return of 5.2% and a 51.86% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as Brookdale Senior Living, CVS Health, and Tenet Healthcare.

In addition to RBC Capital, Tenet Healthcare also received a Buy from Truist Financial’s David S Macdonald in a report issued on February 17. However, on February 13, TipRanks – Anthropic downgraded Tenet Healthcare (NYSE: THC) to a Hold.

Based on Tenet Healthcare’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.53 billion and a net profit of $371 million. In comparison, last year the company earned a revenue of $5.07 billion and had a net profit of $318 million

Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of THC in relation to earlier this year. Most recently, in December 2025, Nadja West, a Director at THC sold 2,178.00 shares for a total of $430,089.66.